After three combat deployments in Afghanistan, army ranger Jesse Gould says he came home with more than the memory of war. He suffered traumatic brain injuries from concussive blasts, developed post-traumatic stress disorder and, by his own account, drank almost every night to cope.
Now 38, Gould is running psilocybin retreats for people with PTSD before the treatment has received FDA approval. His experience reflects a wider debate over the use of so-called magic mushrooms in mental health care, especially for veterans who have not found lasting relief through conventional treatment.
In hardship, Gould said, veterans often turn to medication and talk therapy. But he described that approach as something closer to maintenance than a full recovery. He said he did not want to spend the rest of his life on medication.
Researchers have said psilocybin can help reduce traumatic symptoms in some patients, but they also urge caution. The evidence is still developing, and specialists warn that expanding access too quickly could outpace the science and the safeguards needed to use the drug responsibly.
Searching for another path
Gould’s decision to explore psilocybin grew out of his own struggle after military service. He said he was still young when he began looking for alternatives and wanted a treatment that offered more than symptom management.
That search has placed him among a growing number of advocates who see psychedelic therapy as a possible option for veterans with PTSD. Supporters argue that conventional care does not work for everyone, and that some people continue to struggle despite medication and therapy.
At the same time, the shift toward psychedelic treatment remains controversial. Psilocybin is still not FDA approved, and experts continue to debate how it should be studied, regulated and made available to patients.
States are moving more quickly than federal regulators, expanding access to psychedelic substances in different ways. That has intensified public interest in whether treatments like psilocybin could become part of mainstream mental health care before the clinical and regulatory questions are fully settled.
For Gould, the issue is personal as well as political. His story highlights both the frustration many veterans feel with existing PTSD care and the hope that new approaches may offer something different.
Researchers, however, continue to stress caution. While psilocybin has shown promise in some studies involving traumatic symptoms, the treatment is not yet an approved standard of care, and its long-term risks and benefits are still being examined.
As the debate continues, veterans like Gould remain at the center of a larger question: whether psychedelic therapy will eventually become a regulated medical option, or remain an experimental path pursued ahead of formal approval.
